News pertaining to biosimilars came at a fast and furious pace in 2023.This was the year of the big “deluge” in biosimilars, including those designated as interchangeable, hitting the rheumatology market in the United States. As many as nine...

News pertaining to biosimilars came at a fast and furious pace in 2023.
This was the year of the big “deluge” in biosimilars, including those designated as interchangeable, hitting the rheumatology market in the United States. As many as nine biosimilars for adalimumab (Humira, AbbVie) alone became available for the first time for U.S. patients, with other biosimilars for ustekinumab (Stelara, Amgen) and tocilizumab (Actemra, Genentech) making headlines.
Below are some of the news and feature highlights to help readers gain a deeper understanding of how patient care and prescribing

View Entire Post